LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 25.56

Change

-0.08 (-0.31)%

Market Cap

CAD 0.01B

Volume

1.70K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.17 (+0.62%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 4.87B
PHYS-U:CA Sprott Physical Gold Trust

+0.24 (+1.33%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

-0.11 (-0.16%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

-0.07 (-0.17%)

CAD 3.92B
XEQT:CA iShares Core Equity Portfolio

-0.11 (-0.36%)

CAD 3.86B
CEF-U:CA Sprott Physical Gold and Silve..

+0.69 (+3.15%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.58 (+5.92%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.11 (-0.49%)

CAD 2.78B
NUBF:CA NBI Unconstrained Fixed Income..

-0.10 (-0.47%)

CAD 2.52B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.44% 62% D 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.44% 62% D 59% D-
Trailing 12 Months  
Capital Gain 5.19% 43% F 49% F
Dividend Return 1.32% 55% F 24% F
Total Return 6.50% 46% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.91% 58% F 49% F
Dividend Return 2.02% 59% D- 43% F
Total Return 0.11% 62% D 15% F
Risk Return Profile  
Volatility (Standard Deviation) 5.42% 68% D+ 86% B+
Risk Adjusted Return 37.23% 71% C- 61% D-
Market Capitalization 0.01B 24% F 10% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.